{
  "id": 16905050,
  "title": "Lilly shuffles business structure; Novartis writes off part of Avidity deal",
  "url": "https://urgent.news/2026/10/28/lilly-shuffles-business-structure-novartis-writes-off-part-of-avidity",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-28T13:27:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/lilly-global-markets-novartis-avidity-astellas-talzenna-prana/872857/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "After $1.9B impairment hit, Novartis stands by $12B bet on Avidity",
        "url": "https://urgent.news/2026/10/27/after-1-9b-impairment-hit-novartis-stands-by-12b-bet-on-avidity",
        "published": "2026-10-27T10:57:52.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}